Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$537.92 -0.5%	$586.40	$379.39 ▼ $678.21	$32.85B	0.39	326,238 shs	252,942 shs
BNTX BioNTech	$104.40 -0.5%	$102.02	$76.53 ▼ $131.49	$25.10B	1.29	949,716 shs	894,938 shs
SGEN Seagen	$228.74	$228.74	$123.77 ▼ $228.96	$42.93B	0.32	1.48 million shs	86 shs
TECH Bio-Techne	$50.13 +1.3%	$49.53	$46.01 ▼ $83.62	$7.86B	1.38	1.42 million shs	2.16 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	-8.32%	-6.98%	-12.54%	+42.32%
BNTX BioNTech	0.00%	-0.50%	+2.63%	+9.46%	+21.02%
SGEN Seagen	0.00%	0.00%	0.00%	0.00%	0.00%
TECH Bio-Techne	0.00%	-2.72%	+1.21%	-17.29%	-32.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	4.4169 of 5 stars	4.5	4.0	0.0	0.0	2.6	1.7	2.5
BNTX BioNTech	2.8736 of 5 stars	4.4	3.0	0.0	0.0	2.3	0.8	0.0
SGEN Seagen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TECH Bio-Techne	4.8779 of 5 stars	4.2	3.0	1.7	4.2	2.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.05	Buy	$709.18	31.84% Upside
BNTX BioNTech	2.83	Moderate Buy	$137.86	32.05% Upside
SGEN Seagen	0.00	N/A	N/A	N/A
TECH Bio-Techne	2.45	Hold	$72.00	43.63% Upside

Current Analyst Ratings Breakdown

Latest BNTX, ARGX, SGEN, and TECH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/11/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/10/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00
6/5/2025	TECH Bio-Techne	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
6/3/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$151.00 ➝ $155.00
6/2/2025	BNTX BioNTech	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$112.00
5/30/2025	TECH Bio-Techne	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$59.00
5/29/2025	BNTX BioNTech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$110.00
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	14.58	$2.97 per share	181.09	$90.49 per share	5.94
BNTX BioNTech	$2.98B	8.43	N/A	N/A	$87.61 per share	1.19
SGEN Seagen	$2.30B	18.66	N/A	N/A	$15.10 per share	15.15
TECH Bio-Techne	$1.16B	6.78	$2.31 per share	21.66	$13.13 per share	3.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$16.21	33.18	49.58	0.97	40.20%	16.15%	14.33%	7/24/2025 (Estimated)
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
SGEN Seagen	-$610.31M	-$4.01	N/A	N/A	N/A	-32.61%	-28.06%	-20.92%	N/A
TECH Bio-Techne	$168.10M	$0.82	61.13	25.45	2.65	10.89%	13.17%	10.17%	8/6/2025 (Estimated)

Latest BNTX, ARGX, SGEN, and TECH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/7/2025	Q3 2025	TECH Bio-Techne	$0.51	$0.56	+$0.05	$0.14	$317.92 million	$316.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
SGEN Seagen	N/A	N/A	N/A	N/A	N/A
TECH Bio-Techne	$0.32	0.64%	N/A	39.02%	N/A

Latest BNTX, ARGX, SGEN, and TECH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/19/2025	TECH Bio-Techne	quarterly	$0.08	0.67%	5/19/2025	5/19/2025	5/30/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	7.29	6.68
BNTX BioNTech	0.01	10.18	10.02
SGEN Seagen	N/A	2.67	2.12
TECH Bio-Techne	0.16	3.71	2.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BNTX BioNTech	15.52%
SGEN Seagen	84.26%
TECH Bio-Techne	98.95%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BNTX BioNTech	19.20%
SGEN Seagen	25.90%
TECH Bio-Techne	3.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.06 million	59.58 million	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
SGEN Seagen	3,256	187.70 million	139.08 million	Optionable
TECH Bio-Techne	3,100	156.77 million	150.65 million	Optionable

BNTX, ARGX, SGEN, and TECH Headlines

Recent News About These Companies

Bio-Techne Corp (NASDAQ:TECH) Given Average Rating of "Hold" by Brokerages

June 18 at 5:13 AM | americanbankingnews.com

Mn Services Vermogensbeheer B.V. Sells 6,200 Shares of Bio-Techne Corp (NASDAQ:TECH)

June 18 at 4:06 AM | marketbeat.com

Bio-Techne Corp (NASDAQ:TECH) Receives Consensus Rating of "Hold" from Brokerages

June 18 at 3:56 AM | marketbeat.com

Conestoga Capital Advisors LLC Has $19.30 Million Stock Position in Bio-Techne Co. (NASDAQ:TECH)

June 17 at 5:20 AM | marketbeat.com

Assenagon Asset Management S.A. Has $3.07 Million Holdings in Bio-Techne Co. (NASDAQ:TECH)

June 17 at 3:35 AM | marketbeat.com

Bio-Techne: Solid Financial Ground In The Face Of Macroeconomic Uncertainty

June 16, 2025 | seekingalpha.com

SG Americas Securities LLC Grows Stake in Bio-Techne Co. (NASDAQ:TECH)

June 15, 2025 | marketbeat.com

Here’s What Pulled Down Bio-Techne Corporation (TECH)

June 13, 2025 | msn.com

Bio-Techne Co. (NASDAQ:TECH) Shares Bought by Fort Washington Investment Advisors Inc. OH

June 13, 2025 | marketbeat.com

49,272 Shares in Bio-Techne Co. (NASDAQ:TECH) Acquired by Harbor Capital Advisors Inc.

June 12, 2025 | marketbeat.com

Analysts Are Neutral on These Healthcare Stocks: AbbVie (ABBV), Bio-Techne (TECH)

June 12, 2025 | theglobeandmail.com

First Citizens Bank & Trust Co. Sells 109,938 Shares of Bio-Techne Co. (NASDAQ:TECH)

June 11, 2025 | marketbeat.com

Cyclopharm Secures U.S. Patent Extension for Technegas® to 2031

June 10, 2025 | tipranks.com

Exosome Research Market worth US$480.6 million by 2030 with 17.5% CAGR | MarketsandMarkets™

June 10, 2025 | informazione.it

TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts

June 10, 2025 | finance.yahoo.com

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

June 10, 2025 | prnewswire.com

GAMMA Investing LLC Purchases 102,345 Shares of Bio-Techne Co. (NASDAQ:TECH)

June 10, 2025 | marketbeat.com

Rhumbline Advisers Buys 39,345 Shares of Bio-Techne Co. (NASDAQ:TECH)

June 8, 2025 | marketbeat.com

Bio-Techne (NASDAQ:TECH) Lowered to "Hold" Rating by Wall Street Zen

June 8, 2025 | marketbeat.com

Why Is Techne (TECH) Down 3% Since Last Earnings Report?

June 6, 2025 | zacks.com

Bio-Techne: Slow Growth Amidst Healthcare Policy, MAHA Movement

June 6, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX, ARGX, SGEN, and TECH Company Descriptions

argenex NASDAQ:ARGX

$537.92 -2.79 (-0.52%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$553.00 +15.08 (+2.80%)

As of 06/18/2025 06:26 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech NASDAQ:BNTX

$104.40 -0.57 (-0.54%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$104.88 +0.48 (+0.46%)

As of 06/18/2025 07:20 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Bio-Techne NASDAQ:TECH

$50.13 +0.63 (+1.27%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$50.14 +0.02 (+0.03%)

As of 06/18/2025 07:48 PM Eastern

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time